Articles from Ariceum Therapeutics

Ariceum Therapeutics Doses First Patient in SANTANA-225 Phase 1/2 Clinical Trial of 225Ac-SSO110 in Patients with Extensive-Stage Small Cell Lung Cancer or Merkel Cell Carcinoma

225Ac-SSO110 has received U.S. FDA Orphan Drug Designation

By Ariceum Therapeutics · Via GlobeNewswire · November 11, 2025

Ariceum Therapeutics Data at the 2025 European Association of Nuclear Medicine Annual Congress Further Supports the Advancement of 225Ac-SSO110 for Extensive Stage Small Cell Lung Cancer and Merkel Cell Carcinoma

Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study design of 225Ac-SSO110 in patients with ES-SCLC or MCC

By Ariceum Therapeutics · Via GlobeNewswire · October 9, 2025

Ariceum Therapeutics Appoints David Schilansky as Chief Executive Officer and Announces New Leadership to Advance Next Phase of Development

David Schilansky transitions to CEO, bringing 25 years of company-building, scaling and financing to advance Ariceum’s pipeline of novel radiotherapeutics

By Ariceum Therapeutics · Via GlobeNewswire · August 26, 2025